Compare IMTE & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMTE | NUWE |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | Australia | United States |
| Employees | N/A | 38 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.7M |
| IPO Year | 2016 | N/A |
| Metric | IMTE | NUWE |
|---|---|---|
| Price | $0.60 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.8K | 76.6K |
| Earning Date | 10-22-2024 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.14 |
| Revenue Next Year | N/A | $18.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.19 |
| 52 Week High | $2.54 | $25.95 |
| Indicator | IMTE | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 35.88 |
| Support Level | $0.50 | $0.20 |
| Resistance Level | $0.76 | $2.86 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 31.29 | 31.48 |
Integrated Media Technology Ltd is mainly engaged in the business of manufacture and sale of nano-coated plates for filters, the manufacture and sale of electronic glass, Halal certification and distribution of Halal products, and new energy products and services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.